April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Self-Assembled Dorzolamide/-Cyclodextrin Microparticle Eye Drops
Author Affiliations & Notes
  • Phatsawee Jansook
    Pharmaceutical Sciences,
    University of Iceland, Reykjavik, Iceland
    Oculis Inc., Reykjavik, Iceland
  • Thorsteinn Loftsson
    Pharmaceutical Sciences,
    University of Iceland, Reykjavik, Iceland
    Oculis Inc., Reykjavik, Iceland
  • Einar Stefansson
    University of Iceland, Reykjavik, Iceland
    Oculis Inc., Reykjavik, Iceland
  • Footnotes
    Commercial Relationships  Phatsawee Jansook, Oculis Inc. (E); Thorsteinn Loftsson, None; Einar Stefansson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 235. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Phatsawee Jansook, Thorsteinn Loftsson, Einar Stefansson; Self-Assembled Dorzolamide/-Cyclodextrin Microparticle Eye Drops. Invest. Ophthalmol. Vis. Sci. 2011;52(14):235.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To develop novel aqueous dorzolamide eye drop formulation containing self-assembled drug/cyclodextrin (drug/CD) microparticles that enhance and prolong drug delivery to the eye.


The dorzolamide eye drop vehicle containing γCD microparticles and hydroxypropylmethylcellulose (HPMC) was developed. Physicochemical characterization and in vivo studies in rabbits were performed. The study adhered to the ARVO declaration for the use of laboratory animals in research. Ocular drug distribution was quantitative determination by UPLC-MS/MS systems.


The physicochemical properties of 3% w/v dorzolamide eye drop suspension (3%doz.) complied with the specifications of the eye drop suspension monograph of the European Pharmacopoeia. The in vivo testing of the formulation showed that the maximum dorzolamide concentration (Cmax) in aqueous humor after topical administration of 3%doz. and the commercially available 2% w/v dorzolamide eye drop solution (Trusopt®) was 5.4±3.6 and 2.2±1.5 µg/ml at tmax of 4 and 2 h, respectively (p<0.05) (Fig. 1). The dorzolamide concentration in aqueous humor at 4 and 8 h after single administration of 3%doz. was 13-fold and 45-fold higher, respectively, than that obtained after administration of Trusopt®. The eye drop suspension provided the sustained high dorzolamide concentrations for up to 24 h while the Trusopt® the dorzolamide concentration in aqueous humor was essentially zero 8 h after its administration (Fig. 1). Furthermore, this formulation delivered the drug to the posterior segment of the eye after topical administration.


The development of dorzolamide eye drop microparticle suspension containing γCD and HPMC as complexing and stabilizing agents, respectively, resulted in successful dorzolamide delivery to the aqueous humor and the posterior segment of the eye. This formulation has the potential of being developed into a once-a-day eye drop formulation leading to improve patient compliance.  

Keywords: carbonic anhydrase • drug toxicity/drug effects • development 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.